Breaking News by Dementia and cognitive disorders Panel

This year, at the upcoming 37th ECTRIMS congress, the ECTRIMS-EAN Session, chaired by Profs. Massimo Filippi, Mar Tintoré, Maria Pia Amato and Celia Oreja-Guevara, will discuss two key aspects of MS management: the consensus regarding vaccinations in people with MS and the updated guidelines for MS treatment.

Retrospective analysis of consecutive PD patients seen in an outpatient Movement Disorders Clinic during 2 months, to explore the frequency of ICD during the preceding 2-month lockdown period, and comparison with an equivalent control group.

In this article the authors aimed to uncover if headache patients develop more headaches after COVID-19 mRNA vaccination than healthy controls.

The aim of the present study was to administer the COMPASS-31 questionnaire to a sample of post-COVID patients with and without neurological complaints.

In this article the authors present a systematic review, carried out according to the Preferred Reporting Items for Systematic Review standards, of the neuropathological features of COVID-19.

The aim of this study was to conduct a review on the literature on objective cognitive impairment in patients after COVID-19.

In this study the authors retrospectively analyzed motor symptoms of longitudinally followed PD patients (n = 264) and compared motor disease progression before and during the COVID-19 pandemic.

Review of literature regarding mechanisms of acute and chronic neurological disorders in association with COVID-19.

In this review, the authors discuss contemporary methodologies employed to investigate possible associations between vaccination and adverse neurological outcomes and why determining causality can be challenging.

This cohort study evaluates the COVID-19-related case fatality rate (CFR) of patients with pre-existing neurological diseases.

In this article the authors performed a systematic literature review on neuropathological studies in COVID-19, including 438 patients from 45 articles published by April 22, 2021.

The objective of this study was to investigate the seroprevalence and the quantity of SARS-CoV-2 antibodies in a cohort of patients with MS or NMO-SD. Blood samples were collected in patients diagnosed with COVID-19.

This critical review highlights the injury pathways possible through SARS-CoV-2 infection that have the potential to increase and contribute to cognitive impairment and dementia.

In this article the authors searched 3 databases (PubMed, MEDLINE, and CINAHL) with search terms COVID-19, novel coronavirus, stroke, and cerebrovascular accident.